Polatuzumab Vedotin plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL): Results from the Phase III POLARIX Study

Neha Mehta-Shah,[1] Hervé Tilly,[2] Franck Morschhauser,[3] Laurie H. Sehn,[4] Jonathan W. Friedberg,[5] Marek Trněný,[6] Jeff P. Sharman,[7] Charles Herbaux,[8] John M. Burke,[9] Matthew Matasar,[10] Shinya Rai,[11] Koji Izutsu,[12] Lucie Oberic,[13] Adrien Chauchet,[14] Wojciech Jurczak,[15] Yuqin Song,[16] Richard Greil,[17] Larysa Mykhalska,[18] Juan Miguel Bergua-Burgués,[19] Matthew C. Cheung,[20] Antonio Pinto,[21] Ho-Jin Shin,[22] Greg Hapgood,[23] Eduardo Munhoz,[24] Pau Abrisqueta,[25] Jyh-Pyng Gau,[26] Jamie Hirata,[27] Yanwen Jiang,[27] Mark Yan,[28] Calvin Lee,[27] Christopher Flowers,[29] Gilles Salles[30]

Summary

R-CHOP is the current standard of care for patients with newly diagnosed DLBCL; however, approximately 40% of patients are not cured and an unmet need remains for patients with previously untreated disease.

POLARIX is a Phase III study of Pola-R-CHP vs R-CHOP in patients with previously untreated DLBCL.

The proportion of patients surviving at 2 years was significantly higher with Pola-R-CHP (76.7%) compared with R-CHOP (70.2%); an absolute difference of 6.5%.

The safety profiles of Pola-R-CHP and R-CHOP were comparable.

These results support the use of Pola-R-CHP in the initial management of patients with DLBCL.

Data first presented at the 63rd ASH Annual Meeting, December 11–14, 2021, Atlanta, GA

[1]Washington University in St. Louis, St. Louis, MO, USA; [2]Department of Hematology and U1245, Centre Henri Becquerel and University of Rouen, Rouen, France; [3]Univ. Lille, CHU Lille, ULR 7365 – GRITA – Group de Recherche sur les formes Injectables et les Technologies Associées, Lille, France; [4]BC Cancer Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, Canada; [5]Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA; [6]First Faculty of Medicine, Charles University, General Hospital, Prague, Czech Republic; [7]Willamette Valley Cancer Institute/US Oncology, Eugene, OR, USA; [8]CHU de Montpellier, Montpellier, France; [9]Rocky Mountain Cancer Centers/US Oncology, Aurora, CO, USA; [10]Memorial Sloan Kettering Cancer Center, New York City/Montvale, NY/NJ, USA; [11]Department of Hematology and Rheumatology, Kindai University, Faculty of Medicine, Osaka-Sayama City, Japan; [12]National Cancer Center Hospital, Tokyo, Japan; [13]Institut Universitaire du Cancer, Toulouse-Oncopole, Toulouse, France; [14]CHRU Besançon, Besançon, France; [15]Maria Sklodowska – Curie National Research Institute of Oncology, Kraków, Poland; [16]Peking University Cancer Hospital, Beijing, China; [17]Paracelsus Medical University, Salzburg Cancer Research Institute-CCCIT and Cancer Cluster Salzburg, Salzburg, Austria; [18]Clinical Hospital Feofaniya, Kyiv, Ukraine; [19]Hospital San Pedro de Alcántara, Cáceres, Spain; [20]Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada; [21]Hematology-Oncology & Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS, Naples, Italy; [22]Division of Hematology-Oncology, Department of Internal Medicine, Medical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea; [23]Princess Alexandra Hospital, Brisbane, Australia; [24]Hospital Erasto Gaertner, Curitiba, Brazil; [25]Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; [26]Taipei Veterans General Hospital, Taipei, Taiwan; [27]Genentech, Inc., South San Francisco, CA, USA; [28]Hoffmann-La Roche Ltd, Mississauga, Canada; [29]MD Anderson Cancer Center, Houston, TX, USA; [30]Memorial Sloan Kettering Cancer Center, New York City, NY, USA.

Background

- The current standard of care for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) is R-CHOP; however, approximately 40% of patients are not cured,[1,2] and an unmet need remains for patients with previously untreated disease.
- Polatuzumab vedotin, a CD79b-targeting antibody–drug conjugate, is approved in relapsed/refractory DLBCL in combination with bendamustine and rituximab, and has also demonstrated promising first-line activity when combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) in a Phase Ib/II study.[3]
- Here we report the efficacy and safety analysis from the Phase III POLARIX study (NCT03274492),[4] which compared the efficacy and safety of Pola-R-CHP vs R-CHOP in patients with previously untreated DLBCL.

Study design

- Double-blind, placebo-controlled, international study of patients with previously untreated DLBCL and an International Prognostic Index (IPI) of 2–5.
- Patients were randomised 1:1 to receive six cycles of Pola-R-CHP (with a vincristine placebo) or R-CHOP (with a polatuzumab vedotin placebo); all patients also received two additional cycles of rituximab (**Figure 1**).
- The primary efficacy endpoint was investigator-assessed progression-free survival (PFS).
- Key secondary endpoints included investigator-assessed event-free survival (EFS), independent review committee-assessed complete response (CR) rate at end-of-treatment by positron emission tomography-computed tomography (PET-CT), disease-free survival (DFS), overall survival (OS) and safety.

Figure 1. Study design.



*IV on Day 1; †R-CHOP: IV rituximab 375mg/m², cyclophosphamide 750mg/m², doxorubicin 50mg/m², and vincristine 1.4mg/m² (max. 2mg) on Day 1, plus oral prednisone 100mg once daily on Days 1–5. DLBCL, diffuse large B-cell lymphoma; IPI, International prognostic index; IV, intravenous; ECOG PS, Eastern Cooperative Oncology Group performance status; Pola-R-CHP, polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone; R, randomised; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.

Patient population

- Overall, 879 patients were randomised, 440 to Pola-R-CHP and 439 to R-CHOP (**Table 1**).
- Median age was 65 (range 19–80) years, and the majority of patients had an IPI 3–5 (62.0%).

Table 1. Baseline characteristics.

ITT population	Pola-R-CHP (n=440)	R-CHOP (n=439)
Age in years, median (range)	65.0 (19–80)	66.0 (19–80)
Sex, n (%)		
Male	239 (54)	234 (53)
ECOG PS, n (%)		
0–1	374 (85)	363 (83)
2	66 (15)	75 (17)
Presence of bulky disease (≥7.5cm), n (%)	193 (44)	192 (44)
Elevated LDH, n (%)	291 (66)	284 (65)
Time from diagnosis to treatment initiation, days	26	27
Ann Arbor stage III/IV, n (%)	393 (89)	387 (88)
Extranodal sites ≥2, n (%)	213 (48)	213 (49)
IPI score, n (%)		
2	167 (38)	167 (38)
3–5	273 (62)	272 (62)
Cell of origin, n (%)*		
ABC	102 (31)	119 (35)
GCB	184 (56)	168 (50)
Unclassified	44 (13)	51 (15)
Double-expressor (IHC of MYC and BCL2), n (%)*	139 (38)	151 (41)
Double-/triple-hit lymphoma, n (%)*†	26 (8)	19 (6)

*In the Pola-R-CHP and R-CHOP groups, respectively, the numbers of patients evaluable for COO were 330 and 338, with IHC for MYC/BCL2 expression were 362 and 366, and with FISH for MYC/BCL2/BCL6 rearrangements were 331 and 334; †MYC-rearrangement with BCL2 and/or BCL6 rearrangement.
ABC, activated B-cell; COO, cell-of-origin; ECOG PS, Eastern Cooperative Oncology Group performance status; FISH, fluorescence in situ hybridization; GCB, germinal centre B-cell; IHC, immunohistochemistry; IPI, International prognostic index; ITT, intent-to-treat; LDH, lactate dehydrogenase; Pola-R-CHP, polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.

Pola-R-CHP significantly improved PFS vs R-CHOP

- The 2-year PFS rate was 76.7% (95% confidence interval [CI]: 72.7–80.8) with Pola-R-CHP vs 70.2% (95% CI: 65.8–74.6) with R-CHOP (Δ=6.5%).
- Pola-R-CHP demonstrated a 27.0% reduction in the relative risk of disease progression, relapse or death vs R-CHOP (hazard ratio [HR] 0.73; 95% CI: 0.57–0.95; P=0.02; **Figure 2**).

Figure 2. Investigator-assessed progression-free survival.



ITT population. Data cut-off: 28 June 2021; median 28.2 months' follow-up.
CI, confidence interval; HR, hazard ratio; NE, not evaluable; PFS, progression-free survival; Pola-R-CHP, polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.

Key secondary endpoints

- EFS favoured Pola-R-CHP compared with R-CHOP (HR 0.75; 95% CI: 0.58–0.96; P=0.02).
- The end-of-treatment PET-CT CR rate was not significantly different with Pola-R-CHP vs R-CHOP (78.0% vs 74.0%; P=0.16); however, DFS suggested responses were more durable with Pola-R-CHP than with R-CHOP (HR 0.70; 95% CI: 0.50–0.98; **Figure 3**).
- There was no difference in OS between treatment arms (HR 0.94; 95% CI: 0.65–1.37; P=0.75; **Figure 4**).

Figure 3. Response rates and disease-free survival.



ITT population. Data cut-off: 28 June 2021; median 28.2 months' follow-up. *DFS defined as the time from the date of the first occurrence of a documented complete response to the date of progression, relapse, or death from any cause for the subgroup of patients with a best overall response of CR.
CI, confidence interval; CR, complete response; DFS, disease-free survival; HR, hazard ratio; ITT, intent-to-treat; NE, not evaluable; Pola-R-CHP, polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone; PR, partial response; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.

Figure 4. Overall survival.



ITT population. Data cut-off: 28 June 2021; median 28.2 months' follow-up. CI, confidence interval; HR, hazard ratio; ITT, intent-to-treat; OS, overall survival; Pola-R-CHP, polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone; PR, partial response; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.

Subsequent treatment for lymphoma

- At the time of data cut-off, 99 (23%) and 133 (30%) patients in the Pola-R-CHP and R-CHOP arms, respectively, had received at least one subsequent anti-lymphoma therapy.
- Fewer patients in the Pola-R-CHP than the R-CHOP arm received subsequent anti-lymphoma therapies across various treatment modalities (**Figure 5**).

Figure 5. Proportion of patients receiving subsequent therapies.



Data cut-off: 28 June 2021. *Subsequent lymphoma treatment was defined as non-protocol anti-lymphoma therapy; †Includes any monotherapy, multi-drug, or cell-based regimen.
CAR-T, chimeric antigen receptor T-cell therapy; Pola-R-CHP, polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; SCT, stem cell transplant.

Safety summary

- Safety profiles were similar with Pola-R-CHP and R-CHOP (**Table 2**).
- The most common grade 3 or 4 adverse events were neutropenia (28.3% in the Pola-R-CHP group and 30.8% in the R-CHOP group), febrile neutropenia (13.8% and 8.0%, respectively), and anaemia (12.0% and 8.4%, respectively, **Figure 6**).
- The frequency and severity of peripheral neuropathy were similar for Pola-R-CHP vs R-CHOP (any grade, 52.9% vs 53.9%; grade 2–3, 13.8% vs 16.7%).

Table 2. Adverse events during treatment period.

n, (%)	Pola-R-CHP (n=435)	R-CHOP (n=438)
Any grade AEs	426 (97.9)	431 (98.4)
Grade 3–4	251 (57.7)	252 (57.5)
Grade 5	13 (3.0)	10 (2.3)
Serious AEs	148 (34.0)	134 (30.6)
AEs leading to:		
Discontinuation of any study drug	19 (4.4)	22 (5.0)
Polatuzumab vedotin / vincristine	19 (4.4)	22 (5.0)
Dose reduction of any study drug	40 (9.2)	57 (13.0)

Safety population. Data cut-off: 28 June 2021
AE, adverse event; Pola-R-CHP, polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.

Figure 6. Common adverse events.



Data cut-off: June 28 2021. Adverse events are Medical Dictionary for Regulatory Activities version 24.0 preferred terms; shown are all-grade adverse events occurring in ≥12% of patients in any treatment arm. *Peripheral neuropathy is defined by standard organ class group of preferred terms.
Pola-R-CHP, polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.

Conclusions

- Pola-R-CHP significantly prolongs PFS compared with R-CHOP (HR 0.73) in patients with intermediate- or high-risk previously untreated DLBCL.
- The proportion of patients surviving at 2 years was significantly higher with Pola-R-CHP compared with R-CHOP (76.7% vs 70.2%, respectively); an absolute difference of 6.5%.
- The safety profiles of Pola-R-CHP and R-CHOP were comparable.
- These results support the use of Pola-R-CHP in the initial management of patients with DLBCL.

Presented at 2022 Pan Pacific Lymphoma Conference | 18–22 July

References

1. Sehn LH and Salles G. New Engl J Med 2021;384:842–8.
2. Crump M. et al. Blood 2017;130:1800–8.
3. Tilly H, et al. Lancet Oncol 2019;20:998–1010.
4. Tilly H, et al. New Engl J Med 2022;386:351–63.

Acknowledgements

The POLARIX (NCT03274492) study team would like to thank all participating patients and their families, research staff, and the investigators.

Third-party medical writing assistance, under the direction of the authors, was provided by Rachel Bell, PhD, and Lucinda Sinclair, MSc, of Ashfield MedComms, an Ashfield Health company, and was funded by F. Hoffmann-La Roche Ltd.

Disclosures:

N. Mehta-Shah: C4 Therapeutics: Consultancy; Kowa Hakko Kirin: Consultancy; Karyopharm: Consultancy; Ono Pharmaceuticals: Consultancy; Secura Bio: Consultancy; Research Funding; Daiichi Sankyo: Consultancy; Research Funding; AstraZeneca: Research Funding; Bristol-Myers Squibb: Research Funding; Celgene: Research Funding; Innate Pharmaceuticals: Research Funding; RocheGenentech: Research Funding; Corvus Pharmaceuticals: Research Funding; Verastem: Research Funding; **H. Tilly:** Abbvie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Meeting attendance and travel; Research Funding, AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Janssen-Cilag: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees; **F. Morschhauser:** AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Epizyme: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Consultancy, Membership on an entity's Board of Directors or advisory committees; F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Speakers Bureau; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genmab: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Servier: Consultancy; Incyte: Membership on an entity's Board of Directors or advisory committees; **L. Sehn:** Novartis: Consultancy; Genmab: Consultancy; Debiopharm Group: Consultancy; Teva: Consultancy, Research Funding; RocheGenentech: Consultancy, Research Funding; AbbVie: Consultancy; Acerta: Consultancy; Amgen: Consultancy; Apobiologix: Consultancy; AstraZeneca: Consultancy; Celgene: Consultancy; Gilead: Consultancy; Incyte: Consultancy; Janssen: Consultancy; Kite: Consultancy; Karyopharm: Consultancy; LundBeck: Consultancy; Merck: Consultancy; Morphosys: Consultancy; Sandoz: Consultancy; Seattle Genetics: Consultancy; Takeda: Consultancy; TG Therapeutics: Consultancy; Verastem: Consultancy; **M. Trněný:** Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Morphosys: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Portola: Honoraria, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; **J. Sharman:** AbbVie: Consultancy; AstraZeneca: Consultancy; BeiGene: Consultancy; Bristol-Myers Squibb: Consultancy; Lilly: Consultancy; Pharmacyclics LLC, an AbbVie Company: Consultancy; TG Therapeutics: Consultancy; Centessa: Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees; Genentech, Inc.: Consultancy; **C. Herbaux:** Takeda: Honoraria, Research Funding; AbbVie: Honoraria, Research Funding; F. Hoffmann-La Roche Ltd: Honoraria; Janssen: Honoraria; **J. Burke:** Verastem: Consultancy; AstraZeneca: Consultancy; Morphosys: Consultancy; Adaptive Biotechnologies: Consultancy; Epizyme: Consultancy; Kura: Consultancy; AbbVie: Consultancy; BeiGene: Consultancy; Speakers Bureau; Kymera: Consultancy; **M. Matasar:** Memorial Sloan Kettering Cancer Center: Current Employment, Merck Sharp & Dohme: Consultancy, Current holder of individual stocks in a privately-held company, Membership on an entity's Board of Directors or advisory committees; Genentech, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees; F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Other: Support for attending meetings and/or travel, Research Funding; GlaxoSmithKline: Consultancy; Research Funding; Bayer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Other: Support for attending meetings and/or travel, Research Funding; IGM Biosciences: Research Funding; Pharmacyclics: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Research Funding; Epizyme: Consultancy, Membership on an entity's Board of Directors or advisory committees; Other: Support for attending meetings and/or travel; Research Funding; Genmab: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Other: Support for attending meetings and/or travel, Research Funding; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Other: Travel, Accommodations, Expenses; Research Funding; Daiichi Sankyo: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Other: Travel, Accommodations, Expenses; Research Funding; Seattle Genetics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Other: Travel, Accommodations, Expenses; Research Funding; Merck Sharp & Dohme: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Other: Travel, Accommodations, Expenses; Research Funding; Karyopharm: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Other: Travel, Accommodations, Expenses; Research Funding; Epizyme: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Other: Travel, Accommodations, Expenses; Research Funding; Bristol-Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Other: Travel, Accommodations, Expenses; Research Funding; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Other: Travel, Accommodations, Expenses; Research Funding; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Research Funding; **S. Rai:** Chugai Pharmaceutical Co. Ltd: Speakers Bureau; ONO Pharmaceutical Co. Ltd: Speakers Bureau; Janssen Pharmaceutical: Speakers Bureau; Eisai Co., Ltd: Speakers Bureau; **K. Izutsu:** AbbVie: Honoraria; Allergan Japan: Honoraria; AstraZeneca: Honoraria, Research Funding; Bayer: Research Funding; Celgene: Honoraria, Research Funding; Chugai Pharmaceutical: Honoraria, Research Funding; Daiichi Sankyo: Honoraria, Research Funding; Eisai: Honoraria, Research Funding; Fuji Film Toyama Chemical: Honoraria; Genmab: Honoraria, Research Funding; Huya Bioscience: Research Funding; Incyte: Research Funding; Janssen: Honoraria, Research Funding; Kyowa Kirin: Honoraria, Research Funding; MSD: Research Funding; Novartis: Honoraria, Research Funding; Ono Pharmaceutical: Honoraria, Research Funding; Pfizer: Research Funding; Solasia: Research Funding; Symbio: Honoraria; Takeda: Honoraria, Research Funding; Yakult: Research Funding; **L. Oberic:** Celgene: Honoraria; F. Hoffmann-La Roche Ltd: Membership on an entity's Board of Directors or advisory committees; Other: Support for attending meetings and/or travel; Janssen: Honoraria, Other: Support for attending meetings and/or travel; Gilead: Membership on an entity's Board of Directors or advisory committees; Other: Support for attending meetings and/or travel; AbbVie: Other: Support for attending meetings and/or travel; Incyte: Membership on an entity's Board of Directors or advisory committees; **A. Chauchet:** Roche: Consultancy; Janssen: Consultancy; Gilead: Consultancy; **W. Jurczak:** Maria Sklodowska-Curie National Research Institute of Oncology: Current Employment; AstraZeneca, BeiGene, Janssen, Lisvo Oncology, Roche: Research Funding; AbbVie, Astra Zeneca, Bayer, BeiGene, Celtrion, Celgene, Debiopharm, Epizyme, Incyte, Janssen, Lisvo Oncology, Merck, Mei Pharma, Morphosys, Novo Nordisk, F. Hoffman-La Roche, Sandoz, Takeda, TG Therapeutics: Honoraria; **Y. Gen:** Sandoz: Honoraria, Research Funding; Amgen: Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; AstraZeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Beigene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Celltrion: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Bristol-Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; **A Press:** Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Other: Support for attending meetings and/or travel; Gilead Sciences: Honoraria, Membership on an entity's Board of Directors or advisory committees; Other: Support for attending meetings and/or travel; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Other: Support for attending meetings and/or travel; MSD: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Honoraria, Other: Support for attending meetings and/or travel; F. Hoffmann-La Roche Ltd: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings and/or travel; Speakers Bureau; **P. Abrisqueta Costa:** Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Current holder of stock options in a privately-held company; **Y Jiang:** Genentech, Inc.: Current Employment; F. Hoffmann-La Roche Ltd: Current equity holder in publicly-traded company; **C Lee:** Genentech, Inc.: Current Employment; F. Hoffmann-La Roche Ltd: Current equity holder in publicly-traded company; **C Flowers:** AbbVie: Consultancy, Research Funding; Bayer: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Denovo Biopharma: Consultancy; Epizyme: Consultancy, Research Funding; Genentech/Roche: Consultancy, Research Funding; Genmab: Consultancy; Gilead: Consultancy, Research Funding; Karyopharm: Consultancy; Pharmacyclics/Janssen: Consultancy; Seattle Genetics: Consultancy; Spectrum: Consultancy; **G. Salles:** AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses; Research Funding; Celltrion: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Daiichi Sankyo: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Epizyme: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Kite: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Morphosys: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Beigene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Bayer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Janssen-Cilag: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Regenxbio: Consultancy, Honoraria; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Velostoic: Consultancy, Membership on an entity's Board of Directors or advisory committees; Allogene: Consultancy.